Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
about
First-line tandem high-dose chemotherapy and autologous stem cell transplantation versus single high-dose chemotherapy and autologous stem cell transplantation in multiple myeloma, a systematic review of controlled studiesTreatment of autologous stem cell transplant-eligible multiple myeloma patients: ten questions and answersInhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cellsTesting standard and genetic parameters in 220 patients with multiple myeloma with complete data sets: superiority of molecular genetics.Use of bortezomib as induction therapy prior to stem cell transplantation in frontline treatment of multiple myeloma: impact on stem cell harvesting and engraftment.Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategyThe future of autologous stem cell transplantation in myeloma.Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells.The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursingIdentification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.Post-Autologous (ASCT) Stem Cell Transplant Therapy in Multiple MyelomaA high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell linesPreclinical efficacy of sepantronium bromide (YM155) in multiple myeloma is conferred by down regulation of Mcl-1.Influenza a outbreak in an ambulatory stem cell transplant center.Insulin like growth factor binding protein 7 (IGFBP7) expression is linked to poor prognosis but may protect from bone disease in multiple myeloma.Gene-expression signature of benign monoclonal gammopathy evident in multiple myeloma is linked to good prognosis.Drug metabolism and clearance system in tumor cells of patients with multiple myelomaChaetocin: a promising new antimyeloma agent with in vitro and in vivo activity mediated via imposition of oxidative stress.The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cellsFrequent gain of chromosome band 1q21 in plasma-cell dyscrasias detected by fluorescence in situ hybridization: incidence increases from MGUS to relapsed myeloma and is related to prognosis and disease progression following tandem stem-cell transplaGenes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myelomaNY-ESO-1 immunotherapy for multiple myeloma.Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.Eight-year median survival in multiple myeloma after total therapy 2: roles of thalidomide and consolidation chemotherapy in the context of total therapy 1.High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years.Melphalan: old and new uses of a still master drug for multiple myeloma.The Arkansas approach to therapy of patients with multiple myeloma.Krüppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptorInhibition of aurora kinases for tailored risk-adapted treatment of multiple myelomaExpression of genes encoding for proteins involved in heparan sulphate and chondroitin sulphate chain synthesis and modification in normal and malignant plasma cellsAutologous stem cell transplantation and multiple myeloma cancer stem cells.Immunomodulator drug-based therapy in myeloma and the occurrence of thrombosis.Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing.miRNAs in multiple myeloma--a survival relevant complex regulator of gene expressionNEDD8 Inhibition Overcomes CKS1B-Induced Drug Resistance by Upregulation of p21 in Multiple Myeloma.In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
P2860
Q24197999-3DBFF903-0CCE-4A88-B3E8-07F323594B8AQ26851202-3E78C4CF-0151-436D-8803-DCC2CF9533ABQ28487347-B20E3A67-EEDA-424C-A60E-623807891117Q33284138-EEC60FE2-95D1-4C00-A96C-84E117FFB8EFQ33376918-E20E7AB0-4B1D-4590-A0F4-F77303A07D17Q33564854-A3BD1B46-A4B4-4AAA-BD88-8E518811402BQ33748979-93216C03-FD75-4E3C-9F7F-7F7B6B3B4DF4Q33757020-9149181A-84D1-4ABA-8C49-3C2223A86C2DQ33917164-3A09C9EC-D804-4825-AD62-14E9B43EC94BQ34104277-3A000AF9-5BF9-4D42-8FEB-C37A073CC918Q34361282-69FEE40C-785C-4561-9FFB-1789986D2753Q34364560-9923A21F-3DB5-4F25-B31F-B65411711BB8Q34451553-3CEC7931-7743-47B9-8F6E-74CF46C9A1B0Q34694749-0357D0C3-AD3B-4657-9F36-DB6737BA1B84Q34750568-E8EC786D-6F29-471A-89BC-F0026017F7FAQ34786411-7BA552AB-A90B-4FB5-A756-AE7D16D6DAFEQ34801940-8A99F21B-EAC1-43B4-A87D-BE57972BCE01Q35097641-80B75042-38E5-41F6-BF05-9128BD4D5A75Q35628969-C4C7F921-608F-4D0C-9043-90EAA8D5BF63Q35742560-6F6D9378-579B-495C-8BE4-94DA340FA77FQ35750893-55ADCF18-AD8D-4A80-9214-32FB288A4CB6Q35828711-50838DEB-81CD-4B95-B4EE-371E01805C27Q35848978-ACADB4B8-B213-492F-98A7-80567E47DDEEQ35944699-587E8B51-36CB-422A-BC78-B5B4C4CBD65EQ36637651-4DBECC20-801A-400F-BBCE-315F49E89562Q36782357-E660F6E0-B72C-4E8C-B5C3-5C2704BC0EE1Q36831384-E3C7DCB3-F596-4A18-87F4-922DC75D4673Q36902837-C08E5679-806E-47A0-95EA-F2F072CD992BQ36916889-777563EB-16B8-4D44-9053-4C6F068B1BC6Q37028586-208E5BFE-D6E4-473D-8719-373B39212B08Q37144899-2248C15C-157B-4603-A8F2-9091046288A6Q37215171-0936083D-70D5-4CB7-92A3-1949F182118CQ37237509-0B98A89A-E436-4B5B-B810-6FBA97D57E2FQ37314430-67673826-5484-4036-9431-19CFB03A1ED5Q37973864-AE5F6D86-B615-473A-9B19-EA15C4C96F69Q38065298-4A133D8D-93A6-497F-B160-ED56106BB919Q38101343-B82FBE4A-5591-4BA6-B213-4D0444B8FAD3Q38673891-23F34C5A-162E-419D-A208-E489437AE1F3Q38855262-C0769135-C44C-42B5-BD0F-FBDD79BDE17DQ38910971-23AC00E4-4598-44EB-9391-5DE8A1C9A13A
P2860
Total therapy 2 without thalidomide in comparison with total therapy 1: role of intensified induction and posttransplantation consolidation therapies.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Total therapy 2 without thalid ...... ation consolidation therapies.
@en
Total therapy 2 without thalid ...... ation consolidation therapies.
@nl
type
label
Total therapy 2 without thalid ...... ation consolidation therapies.
@en
Total therapy 2 without thalid ...... ation consolidation therapies.
@nl
prefLabel
Total therapy 2 without thalid ...... ation consolidation therapies.
@en
Total therapy 2 without thalid ...... ation consolidation therapies.
@nl
P2093
P50
P1433
P1476
Total therapy 2 without thalid ...... ation consolidation therapies.
@en
P2093
Athanasios Fassas
Erik Rasmussen
Frits van Rhee
Guido Tricot
John Crowley
John Shaughnessy
Joshua Epstein
Klaus Hollmig
Mauricio Pineda-Roman
P304
P356
10.1182/BLOOD-2005-10-4084
P407
P577
2005-12-01T00:00:00Z